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Background: Despite the advances in medical and interventional treatment modalities, some patients develop
epicardial coronary artery reperfusion but not myocardial reperfusion after primary percutaneous coronary
intervention (PCI), known as no-reflow. The goal of this study was to evaluate the safety and efficacy of intracoronary
epinephrine in reversing refractory no-reflow during primary PCI.
Methods: A total of 248 consecutive STEMI patients who had undergone primary PCI were retrospectively evaluated.
Among those, 12 patients which received intracoronary epinephrine to treat a refractory no-reflow phenomenon were
evaluated. Refractory no-reflow was defined as persistent TIMI flow grade (TFG) ≤2 despite intracoronary administration
of at least one other pharmacologic intervention. TFG, TIMI frame count (TFC), and TIMI myocardial perfusion grade
(TMPG) were recorded before and after intracoronary epinephrine administration.
Results: A mean of 333 ± 123 mcg of intracoronary epinephrine was administered. No-reflow was successfully reversed
with complete restoration of TIMI 3 flow in 9 of 12 patients (75%). TFG improved from 1.33 ± 0.49 prior to epinephrine
to 2.66 ± 0.65 after the treatment (p < 0.001). There was an improvement in coronary flow of at least one TFG in 11
(93%) patients, two TFG in 5 (42%) cases. TFC decreased from 56 ± 10 at the time of no-reflow to 19 ± 11 (p < 0.001). A
reduction of TMPG from 0.83 ± 0.71 to 2.58 ± 0.66 was detected after epinephrine bolus (p < 0.001). Epinephrine
administration was well tolerated without serious adverse hemodynamic or chronotropic effects. Intracoronary
epinephrine resulted in significant but tolerable increase in heart rate (68 ± 13 to 95 ± 16 beats/min; p < 0.001)
and systolic blood pressure (94 ± 18 to 140 ± 20; p < 0.001). Hypotension associated with no-reflow developed in
5 (42%) patients. During the procedure, intra-aortic balloon pump counterpulsation was required in two (17%)
patients, transvenous pacing in 2 (17%) cases, and both intra-aortic balloon counterpulsation and transvenous
pacing in one (8%) patients. One patient (8%) died despite all therapeutic measures.
Conclusion: Intracoronary epinephrine may become an effective alternative in patients suffering refractory
no-reflow following primary PCI.
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Figure 1 A flowchart illustrating the selection of study patients.
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No-reflow is defined as the lack of myocardial perfusion
despite opening up the epicardial coronary vessels in the
setting of percutaneous coronary intervention (PCI). For
elective PCIs, the frequency of no-reflow can be re-
ported as 0.6–5%. But, it may be observed in up to 50%
of primary PCI cases [1,2]. The reduction of the benefi-
cial effects of PCI is the main adverse consequence of
no-reflow phenomenon [3,4]. Distal atherothrombotic
embolization, ischemic or reperfusion injury, and sus-
ceptibility of coronary microcirculation to injury are held
responsible for etiopathogenesis of the phenomenon [4].
Thus, pharmacologic and mechanical strategies to treat
no reflow target these mechanisms. In the medical treat-
ment of no-reflow, local vasodilator and local antiplatelet
drugs have been tried extensively. Epinephrine has po-
tent beta-2 receptor agonist properties that mediate
vasodilatation of the arteriolar circulation, as well as the
better known beta-1 agonist properties that increase ino-
tropic and chronotropic stimulation of the myocardium
[5,6]. Although epinephrine has been used clinically to
treat cardiopulmonary arrest, there is a paucity of pub-
lished data regarding its effectiveness in coronary no-
reflow [7]. The potential usage of epinephrine in the
treatment of no-reflow was evaluated in a previous study
in which some promising results were showed [8].
The goal of this study was to evaluate the safety and
efficacy of intracoronary epinephrine in reversing refrac-
tory no-reflow during primary PCI in patients with acute
ST-segment elevated myocardial infarction (STEMI).
Methods
Patients
A total of 248 consecutive STEMI patients who under-
went primary PCI between September 2009 and Novem-
ber 2010 at the Cardiology Department of Ankara
Yuksek Ihtisas Hospital were enrolled retrospectively in
the study. Eligible 12 patients who underwent primary
PCI for acute STEMI within 12 hours following the on-
set of symptoms and received intracoronary epinephrine
to reverse refractory no-reflow during primary PCI were
included in the study. Acute STEMI was diagnosed on
the basis of typical chest pain lasting over 30 minutes,
and ST elevation of ≥1 mm in at least two contiguous
ECG leads and/or ≥2 mm in precordial leads. Exclusion
criterias were systolic blood pressure less than 90 mmHg
at admission, a known allergic reaction to epinephrine,
chronic hemodialysis, pregnancy, rescue intervention
after failed thrombolysis, contraindications to aspirin or
clopidogrel, need for emergent coronary artery bypass
surgery, and inability to provide informed consent.
This study was approved by the Ethics Committee of
the Ankara Yuksek Ihtisas Hospital, Turkey, and has
been performed in accordance with the ethical standardslaid down in the 1964 Declaration of Helsinki and its
later amendments. All patients signed written informed
consent before undergo primary PCI. All the patients
provided consent upon enrolment in the study. A flow-
chart illustrating the selection of study patients is pre-
sented in Figure 1.Echocardiographic assesment
Conventional echocardiography was performed in all pa-
tients before the procedure, and at discharge (6.5 ±
4.3 days). A skilled echocardiographer blind to the clin-
ical features of the patients performed the echocardio-
graphic study using a Vivid 7 (GE Healthcare, Horten,
Norway) ultrasound system. Basic measurements included
left ventricular diameters by 2D echocardiography with
settings per recommendations by the American Society of
Echocardiography [9]. Left ventricular ejection fraction
(LVEF) was calculated by using the biplane method (modi-
fied Simpson's rule) as recommended by the American
Society of Echocardiography [10]. Echocardiograpy was
not performed in 1 patient at discharge due to death of
the patient.
Table 1 Baseline clinical and procedural characteristics of
the patients who receiving intracoronary epinephrine
Characteristics Rate
Gender (% male) 8 (67%)
Age (mean ± SD) 62 ± 12
Comorbid conditions
Diabetes Mellitus 2 (17%)
Hypertension 4 (33%)
Previous CABG 1 (8%)
Lesion location
Left anterior descending 4 (33%)
Circumflex 2 (17%)
Right coronary artery 6 (50%)
Preprocedural angiographic appearance of thrombus* 8 (67%)
TIMI flow grade before epinephrine
TIMI 1 8 (67%)
TIMI 2 4 (33%)
TIMI flow grade after epinephrine
TIMI 1 1 (8%)
TIMI 2 2 (17%)
TIMI 3 9 (75%)
TIMI frame count before epinephrine (mean ± SD) 56 ± 10
TIMI frame count after epinephrine (mean ± SD) 19 ± 11
*Preprocedural thrombus was defined as discrete intraluminal filling defect,
contrast staining, or haze in the target vessel or at the site of the target lesion.
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All participants underwent selective coronary angiog-
raphy with the Judkins technique using the Philips
Angioscop Xray (Integris HM3000, Philips Medical
Systems, Best, The Netherlans). Impaired blood flow was
defined as a reduction in antegrade blood flow (Thromb-
olysis In Myocardial Infarction [TIMI]) following PCI
that was not secondary to abrupt closure, spasm or sig-
nificant stenosis of the original target lesion. All digital
archives were taken at a speed of 25 frames/s. At least
two angiographers assessed each angiogram for TIMI flow
grade (TFG), TIMI myocardial blush grade (TMBG), and
TIMI frame count (TFC). The two readers each graded
the flows as TIMI-0, TIMI-1, TIMI-2 or TIMI-3 flow. To
be considered refractory, TIMI flow ≤2 had to persist des-
pite intracoronary administration of at least one other
pharmacologic intervention (adenosine, calcium channel
blocker, or nitroprusside).
All patients were subjected to oral aspirin (300 mg) and
clopidogrel (300 mg), as well as intravenous 1000 U/kg
unfractionated heparin. In all patients, catheterization was
performed by the percutaneous femoral approach. Before
the PCI, standard left and right coronary angiograms with
at least 2 best projections were obtained for each patient.
The effects of intracoronary epinephrine on qualitative
TFG or TMBG and quantitative TFC were recorded. The
time from cineangiogram documenting no-reflow to epi-
nephrine dose and the time from epinephrine to follow-up
cineangiogram were calculated.
Hemodynamic analysis
Patients were continuously monitored during all proce-
dures. Heart rates and blood pressures records before
and after administration of epinephrine were deter-
mined. Regardless of atrial or ventricular, all tachy or
bradi-arrhythmias after epinephrine were recorded and
analyzed to ascertain adverse clinical effects of epineph-
rine on cardiac hemodynamics. Hypotension was defined
as systolic blood pressure that was <90 mm Hg, or
intraaortic balloon pump (IABP) in order to maintain a
systolic blood pressure >90 mm Hg.
Management of no-reflow
The first medical treatment of no-reflow was left to the
discretion of the operator. All patients received intracor-
onary epinephrine for treatment of refractory no-reflow
at a dose of at least 100 μg (range, 100–400 μg) given
through the central lumen of an over-the-wire balloon
catheter.
Follow-up
The follow-up information was obtained by a telephonic
interview at 4 years. Major adverse cardiac events
(MACE) including re-infarction, revascularization, anddeath, was obtained from hospital records, death certifi-
cates, or telephone contact with relatives of the patient
or referring physician.
Endpoints
Procedural success was defined as ≤50% stenosis, TFG 3,
and/or increase in TMBG at least 1 grade. Recovery of
hemodynamical parameters was accepted as clinical suc-
cess. The data of usage of transvenous pacemaker or
IABP, hemodialysis or mechanical ventilation require-
ment and mortality were collected.
Statistical analysis
Statistical analysis was performed by SPSS 11.5 statistical
software. Results were presented as mean ± standard de-
viation (SD) or number (%) of patients. The comparison
of the data between the two groups was performed by
an unpaired Student′s t test for continuous variables and
by a chi-square test for discrete variables. Categorical
variables were compared using chi-square test. P <0.05
was considered statistically significant.
Results
The clinical and procedural characteristics of the pa-
tients are shown in Table 1. No-reflow was initially
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tients (mean dose, 150 μg), nitroprusside in 16.7% (mean
dose, 250 μg), nitroglycerine in 33.3% (mean dose,
200 μg), and verapamil in 33.3% (mean dose, 300 μg).
After an unsuccessful attempt with one of these drugs,
intracoronary epinephrine was used. The time from
cineangiogram documenting no-reflow to the first epi-
nephrine dose was 8.4 ± 3 min and the time from epi-
nephrine to follow-up cineangiogram was 2.1 ± 1.3 min.
Administration of intracoronary epinephrine (mean
dose, 333 ± 123 μg) resulted in significant overall im-
provement in coronary flow grade from 1.33 ± 0.49 to
2.66 ± 0.65 (p < 0.001). No-reflow was successfully re-
versed with complete restoration of TFG 3 in 9 of 12
patients (75%). There was improvement in coronary
flow of at least one TFG in 11 (93%) patients, two TFG
in 5 (42%) cases. TFC decreased from 56 ± 10 to 19 ±
11 (p < 0.001) (Figure 2). Also, a reduction of TMBG
from 0.83 ± 0.71 to 2.58 ± 0.66 was detected after epineph-
rine bolus (p < 0.001) (Figure 3). No-reflow phenomenon
was resulted with hypotension in 5 (42%) patients. After
administration of intracoronary epinephrine, hypotension
was resolved all but one patient (8%). Mean systolic blood
pressure was 140 ± 20 mmHg at the end of the procedure.
Hemodynamic effects of intracoronary epinephrine are
shown in Table 2.
None of the patients complicated by sustain ventricular
tachycardia. However, non-sustain ventricular tachycardia
was detected in 3 (25%) patients. Atrial arrhythmia was
not detected in any patients. During the procedure, IABP
was required in two (17%) patients, transvenous pacing in
2 (17%) cases, and both IABP and transvenous pacing inFigure 2 TIMI frame count before and after intracoronary epinephrinone (8%) patients. None of the patients required
hemodialysis during hospitalization period. Mechanical
ventilation was required in only one patient (8%). And,
this patient died 22 hours after the procedure, despite in-
tensive medical treatment.
Baseline mean LVEF was increased significantly at dis-
charge from 39.33 ± 6.49 to 42.09 ± 5.52 (p < 0.001). The
decrease in left ventricular diameters was also significant
compared baseline records. (Left ventricular end-diastolic
and end-systolic diameters decreased from 50.50 ± 4.29 to
48.18 ± 3.42, and from 43.90 ± 4.57 to 41.36 ± 4.36, re-
spectively, p <0.001).
Follow-up
During the 4-year follow-up period, 2 patients (17%)
with TFG 2 after intracoronary epinephrine underwent
target lesion revascularization for STEMI; hospitalization
due to heart failure occurred in 1 patient (8%). All pa-
tients were alive at the end of follow-up.
Discussion
Our single center study demonstrated that intracoronary
epinephrine may be an effective option in the patients
with refractory no-reflow following primary PCI for
STEMI. Intracoronary epinephrine resulted in significant
improvement in TFG, TFC, and TMBG in almost all pa-
tients. Moreover, epinephrine administration was well
tolerated without serious adverse hemodynamic or
chronotropic effects.
The results of our study are consistent with a previous
retrospective study conducted by Skelding et al. [8]. They
performed a retrospective analysis of the angiographic,e bolus are shown.
Figure 3 The levels of myocardial blush grade before and after
intracoronary epinephrine bolus are shown.
Aksu et al. BMC Cardiovascular Disorders  (2015) 15:10 Page 5 of 7hemodynamic, and clinical effects of intracoronary epi-
nephrine administered in patients developing refractory
no-reflow following PCI. Of the 29 patients, 7 (24%)
underwent elective PCI, and in 22 others (76%) refractory
no-reflow developed following PCI in the setting of acute
coronary syndromes. In their study, administration of
intracoronary epinephrine resulted in significant improve-
ment in TIMI flow in almost all patients and restored nor-
mal flow in the majority of cases. Unlike the previous
study, only patients with STEMI were included in the
present study.
Although the study by Skelding et al. [8] adds to our
knowledge by providing first information about the
safety and efficacy of intracoronary epinephrine in re-
fractory no-reflow, there remain a number of important
unresolved issues. The optimal dose, route, and fre-
quency of administration for this agent have been shown
to effectively treat no-reflow have not been known
clearly yet. As we mentioned above the final cumulative
dose was not predefined in the previous study. In ourTable 2 Hemodynamic effects of intracoronary epinephrine
Predosage Postdosage
Systolic pressure (mmHg)
94 ± 18 140 ± 20*
Diastolic pressure (mmHg)
61 ± 14 92 ± 16*
Heart rate (beats/min)
68 ± 13 95 ± 16*
*p < 0.001.study, empirical starting dose of epinephrine was 100 μg
and this was increased up to 400 μg based on patient’s
responses.
The mean dose of intracoronary epinephrine was sig-
nificantly higher in our study. Although the exact reason
of this finding cannot be thoroughly understood, a pos-
sible explanation is that six (50%) of the patient necessi-
tated multiple doses in our study. Whereas, multiple
doses of intracoronary epinephrine were given in only 1
(3%) patient in the study mentioned above [8].
The definition of hypotension after no-reflow was not
stated in the previous study. Although the ratio of
hypotensive patients were seen similar between previous
and current studies (48% and 42%, respectively), the only
patients in whom systolic blood pressure decreased sig-
nificantly after no-reflow phenomenon were defined as
hypotension in the present study. A possible explanation
of higher epinephrine administration in the current
study is that the ratio of severe hypotensive cases may
be higher in our study. Our study population consisted
of patients with STEMI and severe hemodynamic in-
stability may be more observed in the STEMI after no-
reflow. These may explain why the patients more resist-
ant to the single dose epinephrine administration in our
study.
As another difference, the effects of intracoronary epi-
nephrine administration patients had been evaluated
only by TFG in the previous study. However, it is well
known that angiographic analysis of TFG is qualitative,
and it does not precisely quantities flow changes or dis-
tinguish microvascular versus myocardial mechanisms of
no-reflow. As quantitative angiographic parameters, TFC
can be used to describe the effectiveness of myocardial
reperfusion more accurately. Furthermore, TMBG is an
independent predictor of long-term mortality [11]. Our
study demonstrated that administration of intracoronary
epinephrine exerts improving effects in quantitative
angiographic parameters (TFC ad TMBG) as well as
TFG. Also, it was confirmed that selective intracoronary
epinephrine administration is safe and well-tolerated.
No-reflow is a relatively common and serious compli-
cation of PCI strategies. It has been demonstrated that
either impaired flow or the absence of flow is associated
with an increased follow-up incidence of myocardial in-
farction and death [12]. The cause of no-reflow after pri-
mary PCI in patients with STEMI is multifactorial.
Endothelial dysfunction, microvascular disorders, spasm,
embolization, and reperfusion injury are thought to be
responsible for etiopathogenesis [13]. Furthermore, ad-
vanced age, delayed reperfusion, a low TIMI flow before
PCI, systolic blood pressure on admission <100 mmHg,
usage of IABP before PCI, a long target lesion and a high
thrombus burden were found as independent predictors
of no-reflow [14]. Thus, pharmacologic strategies for the
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strategies: local vasodilator therapy and local antiplatelet
therapy.
Among the mechanisms responsible from the no-
reflow phenomenon, vasoconstriction is considered one
of the most important and potentially reversible, as sug-
gested by the numerous positive reports of therapeutic
vasodilatation in this context. Epinephrine causes potent
coronary vasodilator effect via β2 receptor activation, in
addition to its chronotropic and inotropic effects on the
heart. Thus, it should not be confusing that intracoron-
ary epinephrine may reveal a beneficial effect on the pre-
vention of the no-reflow in the patients with STEMI.
As a second responsible mechanism, platelet aggrega-
tion may play an important role in the formation of
embolization and thus the occurring of no-reflow.
Glycoprotein ΙΙb/ΙΙΙa inhibitors block the final pathway
of platelet aggregation and should be effective in reducing
both epicardial and microvascular thrombus burden. The
previous studies revealed that early administration of
Glycoprotein IIb/IIIa inhibitors before PCI may improve
early infarct-related artery patency before stenting, the
success rate of the stenting procedure, the rate of coronary
patency at follow-up, left ventricular function, and clinical
outcomes especially among those patients with preproce-
dural TIMI 0 or 1 flow [15-17]. However, there are no
convincing randomized trials in using Glycoprotein IIbIIIa
inhibitors in the treatment of no-reflow, and therefore
their use for treatment of no-reflow is not a guideline
recommendation.
Saito et al. [18] evaluated the effectiveness of pulse in-
fusion thrombolysis in patients with an AMI with a large
(>15 mm) coronary thrombus, focusing on the occur-
rence of the 'no flow' phenomenon. They found that
pulse infusion thrombolysis was effective in preventing
'no flow' in the mechanical revasculalization for AMI es-
pecially those cases with a large thrombus.
Finally, microvascular obstruction (MVO) is another
integral part of myocardial no-reflow. Experimental and
clinical studies demonstrate that ischemic times of 3–4
hours result in irreversible microvascular injury [19].
Magnetic Resonance Imaging (MRI) is the most accurate
method for the evaluation of MVO [20,21]. In a recently
published study, Pernet et al. [22] showed that although
93 to 95% of the patients had a TIMI flow grade =3 after
PCI at 24 h, MVO was diagnosed by MRI in 57% of
cases at day 5 [19].
Although, chronotropic and inotropic effects on the
heart of epinephrine are well known, epinephrine may
show potent beta-2 receptor agonist properties that me-
diate vasodilatation of the arteriolar circulation. This
may be one of the potential explanations of the beneficial
effect on no-reflow phenomenon. In addition, no-reflow
phenomenon is usually presented with hypotension.Intracoronary epinephrine may restore normotension in
these patients, since this agent stimulates alpha vasocon-
strictor receptors. The increase in coronary flow due to
correction of hypotension may be the other potential
mechanism. Despite the encouraging results of our study,
pro-arrhythmic potential of epinephrine and the possibil-
ity of worsening ischemia by increasing myocardial oxygen
demand should be explained by large randomized studies.
Limitations
There are several limitations of our study. The number
of patients is small. Also, the study was designed retro-
spectively and therefore subject to selection bias. Retro-
spective review of data also limits data regarding the
quantitative responses of coronary flow and systemic
hemodynamic to pharmacological interventions.
Theoretically, post-PCI angiographic parameters of
coronary flow may be well if preprocedural Glycoprotein
IIb/IIIa inhibitor loading was done routinely in all pa-
tients. It cannot be concluded if the patients would get
loading of Glycoprotein IIb/IIIa inhibitors, whether use-
ful effects of intracoronary epinephrine change.
At the early phase of STEMI, the successful restoration
of epicardial coronary artery patency does not always pre-
dict to adequate reperfusion at the microvascular level. So,
the other potential limitation of our study is that no pa-
tients were evaluated by MRI to confirm the adequate re-
perfusion at the microvascular level.
Lastly, the follow-up information was obtained by a
telephonic interview. If all patients were evaluated by
echocardiography for left ventricular remodeling at
follow-up, it would help to clarify not only angiographic
but also clinical effects of intracoronary epinephrine
treatment.
Conclusion
In summary, our study revealed that intracoronary epi-
nephrine may exert encouraging effects in patients de-
veloping refractory no-reflow following primary PCI for
STEMI. Intracoronary epinephrine was well tolerated
and resulted in prompt and dramatic recovery of flow in
the majority of patients. Prospective randomized studies
will be necessary to determine whether intracoronary
epinephrine should be used primarily or in combination
with other agents for the treatment of no-reflow.
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